UKINETS2025 23rd National Conference of the UK and Ireland Neuroendocrine Tumour Society 2025 Oral Communications (4 abstracts)
Real-world outcomes for PRRT in patients with well differentiated gastroenteropancreatic neuroendocrine tumours
Christina Nuttall 1 , Manyi Eyong 1 , Sarah McConnell 1 , Katie Dennison 1 , Kelly Farrell 1 , Natalie Barratt 2 , Stephen Jeans 3 , Eleni Vrana 1 , Shaun Alexander 1 , Alison Backen 4,1 , Melissa Frizziero 1 , Amarjot Chander 3 , Thomas Westwood 3 , Prakash Manoharan 3 , Mairéad G. McNamara 4,1 & Richard Hubner 1
1Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom; 2Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United States Minor Outlying Islands; 3Department of Radiology and Nuclear Medicine, The Christie NHS Foundation Trust, Manchester, United Kingdom; 4Division of Cancer Sciences, Faculty of Biology, Medicine and Health, Manchester, United Kingdom
Background: Peptide receptor radionuclide therapy (PRRT) is recommended for patients with somatostatin receptor (SSTR)-positive well differentiated gastroenteropancreatic neuroendocrine tumours (WDGEP-NET) after progression on somatostatin analogue (SSA), but real-world data on outcomes is lacking.
Methods: We collected data on baseline demographics, tumour factors, and outcomes for patients with WDGEP-NET who received PRRT between 2018 and 2023 at a single UK European Neuroendocrine Tumour Society (ENETS) centre of excellence. The primary end point was progression free survival (PFS), secondary outcomes were overall survival (OS), objective response rate (ORR) and adverse events (AEs).
Results: Of 141 patients eligible for inclusion 51% were female, median age 65.3 years, and ECOG Performance status (PS) was 0 (25%), 1 (68%) or 2 (6%). Primary site was small bowel (54%), pancreas (29%), other (14%) or unknown (5%). Tumour grade (G) was 1 (44%), 2 (51%), 3 (1%,) or unknown 4%. Metastatic disease was present in 77% of patients, most commonly lymph node metastases (62%). Radiological progression prior to PRRT was documented in 92% patients, and 98% had received at least one prior systemic therapy (SSA in 78%). Four PRRT cycles were received by 82% patients. At censorship 38% of patients had experienced disease progression and median follow-up was 27.7 months (mo). Overall PFS was 35mths; 44mo and 27mo for G1 and 2 NET respectively (Log-rank Mantel-Cox Chi square 10.7, P = 0.0011); primary site and tumour functionality did not significantly influence PFS. Patients who completed four cycles of PRRT had significantly longer PFS than those who did not (37mo vs 19mo, P = 0.0001). SSA was stopped in 19% patients on completion of PRRT and this did not significantly impact on PFS. OS was 48 mo for all patients and ORR was 9.2 %. G1 and 2 AEs were experienced by 65% and 16% of patients respectively, most commonly fatigue, nausea and diarrhoea. G3 AEs occurred in 4%, and 1 patient experienced a grade 4 AE (thrombocytopenia). There were no treatment related deaths.
Conclusion: PRRT for WDGEP-NET achieves a favourable PFS (better in G1 than 2) and OS, but lower ORR in the real-world setting and is well tolerated.
Volume 114
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2025 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more